Hyndland Partners Logo Hyndland Partners Logo
Hyndland Partners Logo
Contact
INDUSTRY
Healthcare
Our healthcare team consists of advisory professionals with operational experience across healthcare services, life sciences, biotechnology, pharmaceuticals and medical devices
Guiding executives through decisions shaping the future of care

Hyndland Partners’ healthcare team is trusted to lead industry-defining transactions.

We have coverage across healthcare, life sciences, and biotechnology in product, services, and R&D categories.

From advising global pharmaceutical giants to running competitive sales processes for regional market leaders, we are a dynamic team with coverage across the Americas, Europe, Asia, and Oceania. We have relationships with industry executives, policymakers, and investors who shape outcomes, enabling us to advise with clarity and precision.

Our team has advised on public-to-private transactions, represented three Fortune 100 healthcare companies, and is continually called upon to lead high-profile mandates. Clients rely on us for discretion, judgment, and proven capability in executing transactions that shape the global healthcare landscape.

SUB-SECTORS
Extensive Market Coverage
We advise across the legacy and emerging segments that define the global healthcare and life sciences landscape.
Biotechnology
We advise biotech companies spanning therapeutic areas, modalities, and business models — including cell therapy, biologics, and delivery technologies
Healthcare Services
Our experience spans healthcare providers, payors, and outsourced service models, advising on consolidation, investments, and ownership transitions
IT & Digital Health
We work with companies at the intersection of healthcare and technology, advising on transactions that drive digitalisation, insight, and patient experience
Medical Technology & Devices
Advising on transactions for medtech innovators and established device manufacturers across diagnostics, surgical, and therapeutic technologies
Pharmaceuticals
Repeat mandates from specialty pharmaceutical companies on exits, carve-outs, and strategic transactions across the value chain
CLIENTS
Who We Serve
We help public companies, institutional investors, and founder-led businesses navigate M&A and other strategic transactions
Owner-Managed Businesses
We serve as trusted advisors to founder-led and owner-managed businesses in the most pivotal moments
Private Equity and Institutional Investors
Our team supports financial sponsors on acquisitions, exits, and recapitalisations
Corporates and Strategic Acquirers
Public and private corporates engage us to identify, evaluate, and execute acquisitions and divestitures
Venture-Backed Companies
For venture-backed and growth-stage businesses, we help positioning to scale, secure new sources of capital, and lead strategic sales to global acquirers
Boards and C-Suite Executives
Providing independent counsel to boards and senior leaders navigating strategic and transactional decisions
Active conversations with over 15,000 strategics and investors each year...
CASE STUDIES
Global Coverage. Disciplined Execution.
Our transactions reflect more than a decade of commitment to client success, driving positive transformation across global markets.
Slide to See
Advising on Transformational AI Transactions
Advised on a secondary transaction for OpenAI, delivering allocation to new institutional investors.
Advising on Transformational AI Transactions

We advised a late-stage venture capital group on a highly competitive secondary opportunity in OpenAI, one of the most closely held and strategically significant companies in artificial intelligence.

Amid limited liquidity and a carefully managed cap table, we secured direct access to primary equity from existing shareholders, navigating complex transfer mechanics and governance considerations.

Our deep connectivity across private capital and limited partner ecosystems underpins our ability to originate and structure such transactions. We are trusted to manage high-profile deals in frontier markets where discretion and relationships are often more valuable than capital alone.

Delivering Proprietary Deal Flow at Scale for a Leading American Private Equity Firm
We are a long-standing partner to U.S.-based private equity firm, Boyne Capital.
Delivering Proprietary Deal Flow at Scale for a Leading American Private Equity Firm

We are a long-standing partner to Boyne Capital (“Boyne”), a U.S.-based private equity firm targeting lower middle-market deals with up to $100 million in revenue.

Our team is trusted to play a lead role advising on new platform acquisitions and supporting existing portfolio companies with corporate development. Industrials have been a core area of focus, particularly across precision manufacturing, civil engineering, and industrial services.

This ongoing mandate reflects Boyne’s confidence in our ability to deliver differentiated deal flow and counsel where sector expertise is critical to value creation.

As of July 2025, we have supported Boyne on 59 transaction opportunities.

New Harbor Capital Platform Acquisition
New Harbor Capital Partners with MD Esthetics to Drive National Growth
New Harbor Capital Platform Acquisition

We represented New Harbor Capital on its platform acquisition of MD Esthetics.

MD Esthetics is a growing medical aesthetics and wellness business with 12 locations across the US. The deal will support the founders, Dr. Michael Pedro and Danielle Pedro, who have ambitions to expand across the US.

Ed Lhee, Partner at New Harbor Capital:

“We look forward to accelerating their expansion, both organically and through future acquisitions, to solidify their position as a leader in the medical aesthetics and wellness space.”

Strategic Review of Recaro Automotive
Advised specialist automotive investors on the potential acquisition of Recaro.
Strategic Review of Recaro Automotive

We supported several strategic and financial investors in evaluating a potential acquisition of Recaro Automotive, a global leader in premium automotive seating systems.

The mandate involved a review of Recaro’s market position, OEM relationships, contract pipeline, and brand equity across both performance and commercial vehicle segments.

Our track record and network within the automotive sector, coupled with cross-border experience, provided efficient execution support throughout the process.

Advancing Space Propulsion
Advancing next-generation orbital mobility with Impulse Space’s Series C raise.
Advancing Space Propulsion

In June 2025, Impulse Space, a leader in space mobility, successfully closed a $300 million Series C round.

A select pool of institutional capital retained our team following previous successes in adjacent ‘deep tech’ markets.

As one of the largest raises for a space startup, it marked a significant step in the company’s growth trajectory, bringing total funds raised to $525 million.

BY THE NUMBERS
Quantifying our impact
36%
of our healthcare clients are from referrals
25 countries
we have led healthcare deals in 25 countries to date
SERVICES
Comprehensive Coverage
Delivering a complete suite of advisory services to all healthcare, life sciences and biotechnology markets
DEAL SPOTLIGHT
Industry Experience
A selection of transactions demonstrating our results-driven culture and commitment to exceptional client service
Hyndland Partners Appointed to Deploy $125m for Software Group
Client
Redacted
Service
Buy-Side M&A
Sector
Technology
Summary

Hyndland Partners’ was recently appointed by an acquisitive North American software group to advise on the deployment of $125m before 2024.

We are targeting acquisitions of B2B software or technology-enabled businesses with the following characteristics

  • Based in the UK or EEA
  • >$750,000 in TTM EBITDA
  • Over 60% of revenue must be recurring
  • Profitable, or a clear path to profitability within one year
1 of 1 Deal Spotlight
Slide to See
INSIGHTS
Practical insights from experience you can trust
A collection of independent perspectives shaped by decades of hands-on deal execution.
GET STARTED
Begin the Conversation
For a confidential conversation about strategic options or potential transactions, please contact our team.
First Name *
Last Name *
Email *
Phone Number *
How Can We Help? *
21:25
London
05:25
Singapore
16:25
New York
Hyndland Partners Logo
Shaping the future of exceptional businesses.
© 2025 Hyndland Partners